Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCB14-2516
- Development stage
- Preclinical
- Lead developer
- LigaChem Biosciences, Inc.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LCB14-2516 is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), developed for the treatment of multiple myeloma. It consists of an Fc-silenced IgG1 anti-BCMA monoclonal antibody conjugated to a highly potent pyrrolobenzodiazepine (PBD) DNA cross-linking payload using the ConjuAll platform. The ConjuAll technology utilizes a second-generation β-glucuronide (LBG) linker to ensure site-specific conjugation and stability. Preclinical studies indicate that LCB14-2516 exhibits superior efficacy compared to belantamab mafodotin biosimilars in various multiple myeloma models, with the potential for a reduced risk of ocular toxicity (keratopathy) often associated with earlier BCMA-targeted ADCs.
02
Targets
BCMA (B-cell maturation antigen)DNA
Beyond the preview
Go deeper on LCB14-2516.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCB14-2516.